Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 10:2025:607-613.
eCollection 2025.

RD-LIVES: A Living Evidence Synthesis System for Rare Disease Treatment Efficacy and Safety

Jinlian Wang  1 , Hui Li  1 , Hongfang Liu  1
Affiliations

RD-LIVES: A Living Evidence Synthesis System for Rare Disease Treatment Efficacy and Safety

Jinlian Wang et al. AMIA Jt Summits Transl Sci Proc. .

Abstract

Although rare diseases (RD) are gaining priority in healthcare worldwide, developing research policies for studying them in public settings remains challenging due to the limited evidence available. Evidence generation is crucial for rare diseases, requiring systematic assessment of study quality across multiple sources. Given the scarcity of patients, literature and clinical trial data for orphan drugs, we developed RD-LIVES-a tool designed to automatically accelerate evidence collection from literature and clinical trials for systematic reviews and meta-analyses. This tool enhances our understanding of treatment outcomes, determines appropriate follow-up durations, and informs the required treatment impact size for new drugs. Using Idiopathic Pulmonary Fibrosis (IPF) as an example, we demonstrate how RD-LIVES automates evidence collection and element extraction. The results indicate that RD-LIVES plays a vital role in designing costly prospective trials and has the potential to increase the likelihood of successful trial outcomes.

Keywords: IPF; Idiopathic Pulmonary Fibrosis; forced vital capacity; meta-analysis; overall survival; pirfenidone; progression-free survival; systematic review.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
RD-LIVES workflow
None
None
None
None
None
None
None
See this image and copyright information in PMC

References

    1. Council Recommendation of 8 June 2009 on an Action in the Field of Rare Diseases Official Journal of the European Union. 2009/C 151/02.
    1. Cote A, Keating B. What is Wrong with Orphan Drug Policies? Value Health. 2012 Dec;15(8):1185–91. - PubMed
    1. Kanavos P, Nicod E. What is Wrong with Orphan Drug Policies? Suggestions for Ways Forward. Value Health. 2012 Dec;15(8):1182–4. - PubMed
    1. Kanters TA, de Sonneville-Koedoot C, Redekop WK, Hakkaart L. Systematic Review of Available Evidence on 11 High-priced Inpatient Orphan Drugs. Orphanet J Rare Dis. 2013 Aug 16;8:124. - PMC - PubMed
    1. Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL. Systematic Review of Comparative Effectiveness Data for Oncology Orphan Drugs. Am J Manag Care. 2012 Jan;18(1):47–62. - PubMed

LinkOut - more resources